Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Genome Medicine

Fig. 2

From: Rational design of cancer gene panels with OncoPaD

Fig. 2

Cost-effectiveness of OncoPaD and widely employed panels. a Cost-effectiveness of pan-cancer panels. The bubble plot presents in the x-axis the cohort coverage of each panel—i.e. proportion of samples of the pan-cancer cohort mutated in genes and/or hotspots of the panel—versus the amount of DNA (Kbps) included in each panel (y-axis). The size of the bubbles represents the proportion of genes in the panel that are cancer driver genes according the four lists integrated in OncoPaD (see “Methods”). Red bubbles correspond to OncoPaD panels focused on drug profiling, i.e. considering as input driver genes drug biomarkers; blue bubbles are OncoPaD panels based on driver genes; gray bubbles represent other widely employed panels. b Cost-effectiveness of panels in the evaluation of solid tumors. c Cost-effectiveness of cancer type-specific panels. OncoPaD panels fine-tuned for glioblastoma (pale green area), breast cancer (pale red area), and colorectal cancer (pale yellow area) were built and assessed in comparison to four pan-cancer and one solid tumor-specific widely employed panels. All data on coverage and DNA amount used to build these graphs is available in Additional file 4: Table S3

Back to article page